Nov 15, 2022 / 12:20PM GMT
Unidentified Analyst -
Running the Tandem Diabetes fireside chat. My name is [Young Li]. I'm one of the analysts on the U.S. Medtech team. I'm very pleased to be joined by John Sheridan, President and CEO; and Leigh Vosseller, EVP, CFO and Treasurer.
Thanks for coming to our conference, guys and looking forward to the chat. So I guess maybe we can spend a minute just talking about the insulin pump market, penetration of the opportunity today? And where do you think this therapy is going over time?
Questions and Answers:
John F. Sheridan - Tandem Diabetes Care, Inc. - President, CEO & DirectorSure. Well, first of all, it's nice to be here. I would say that if you look back over the last couple of years, the insulin pump market has been accelerating. If you were to go back as far as 5 or 6 years ago, there was about 25,000 people, who came from MDI therapy annually to pump therapy. And around 2018, we saw that started to accelerate. I think it was largely driven by new technologies in the marketplace, technologies that reduce the burden of diabetes
Trustpilot
